AdvancePCS copay revenue
Executive Summary
AdvancePCS' revenue and cost of revenue would each increase "15-25%" for FY 2003 if SEC requires reporting of copays to clients as revenue, CEO David Halbert says. FY 2002 revenue without copays totaled $3.4 bil.; that number could grow as large as $4.3 bil. with addition of copay revenue. PBMs are preparing for a Securities & Exchange Commission decision on a uniform standard for copay accounting (1"The Pink Sheet" March 31, p. 26)...
You may also be interested in...
PBM Accounting: Express Scripts Says Retail Rx Copays Are Not Revenue
Express Scripts is urging the Securities & Exchange Commission to avoid setting PBM accounting standards that require companies to count patients' retail pharmacy copayments as revenue
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.